Latest Healthcare News

Inhalerx Limited tapped $247,000 from a $38.5 million funding facility to support its clinical trials, while reporting a $310,000 cash burn in operating activities for the September quarter.

InFocus Group Holdings has launched two new strategic units targeting digital assets and iGaming, backed by a significant loan and guided by a newly formed advisory board featuring industry veterans.

Bridge SaaS Limited reported a robust September quarter, buoyed by its majority-owned Brightside subsidiary's profitability and participant growth, while preparing to launch new NDIS services in New South Wales.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Strategic Elements Ltd has marked a key milestone by successfully fabricating Energy Ink™ prototype cells in a commercial setting, while expanding its artificial intelligence ventures and maintaining a robust financial position.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Oakridge International reports robust Q1 2025 results with strong sales and technology advances, while managing a potential legal claim.

Vection Technologies reports a 60% surge in operating cash flow in Q1 FY26, driven by a landmark $22.3 million Defence framework agreement and a strategic $21 million capital raise. The company is poised for sustainable profitability with a record $75 million contract pipeline through 2028.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.